Bio-Techne has continued to push boundaries in the biotechnology industry, expanding the
AI-Engineered Designer Protein Portfolio to advance cell therapy and regenerative medicine. Challenges in growth and market performance were addressed with resilience, as highlighted during their
Q1 2025 Earnings Call. The company has experienced notable stock movements, from value appreciation to underperforming against competitors. Strategic moves were made including partnering with
Waters Corporation,
Leader Life Sciences and
MedsanTek to expand market access. Meanwhile, JPMorgan Chase & Co. and Toronto Dominion Bank reduced their Bio-Techne holdings. Bio-Techne continues to innovate with the introduction of
ESR1 Mutation Monitoring Assay and a
Next-Generation High Throughput Simple Western System. In spite of mixed financials and a somewhat negative impact on the share price, the company consistently exceeded earnings estimates, thanks to the growth of its diagnostic unit. Bio-Techne has made a series of acquisitions, including
Lunaphore to boost spatial biology in cancer diagnostics, investment in
Wilson Wolf, in addition to submitting an FDA drug master file for Excellerate GMP iPSC Expansion Medium, supporting stem cell therapy.
Bio-Techne Corp TECH News Analytics from Wed, 03 Mar 2021 08:00:00 GMT to Fri, 10 Jan 2025 14:18:46 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -3
